Trustworthy medical team
The Hematologic Malignancy Center at Seoul National University Cancer Hospital provides specialized care for hematologic malignancies such as chronic leukemia, multiple myeloma, malignant lymphoma, myelodysplastic syndrome, and myeloproliferative diseases, as well as hemorrhagic and thromboembolic diseases such as aplastic anemia, deficiency anemia, hemolytic anemia, hemophilia, and venous thrombosis.
Our center delivers the best treatment results by cooperating with top-class experts in related fields for the effective treatment of hematologic malignancies and blood diseases with complex characteristics. To provide accurate diagnoses and monitor treatment responses, we work closely with the Laboratory Medicine Department, the Nuclear Medicine Department, the Radiology Department, and the Pathology Department and perform treatments that require a high level of skills, such as hematopoietic stem cell transplantation, which includes treatments with blood and cell products, apheresis, and cord blood/haploidentical transplantation. We provide customized cancer treatment by using our hematologic gene sequencing service, which is the basis of every customized treatment.
World-class research-centered hospital
Recently, research on molecular targeted therapy and cell therapy products is increasing rapidly, and clinical trials using new drugs/technologies are also quickly increasing. Accordingly, the Hematologic Malignancy Center at Seoul National University Cancer Hospital is leading the research on hematological malignancy by conducting clinical trials on various new drugs and cell therapy products for hematologic malignancies including the “first in human trials.” We have also been participating in the International Cancer Genome Consortium (ICGC), the largest global cooperative researcher in the field of the cancer genome, as a research institute responsible for the genome in the field of hematologic malignancy from 2013 Expanding the clinical trial opportunities to recurrent/intractable hematologic malignancy patients whose treatment options are limited is also one of the missions of the Hematologic Malignancy Center at Seoul National University Cancer Hospital.
Rich experience in hematopoietic stem cell transplantation
The Hematopoietic Stem Cell Transplantation Center at Seoul National University Cancer Hospital is the best in Korea with 2,800 hematopoietic stem cell transplantation cases as of 2020. It has accumulated experience in hematopoietic stem cell transplantations that require a high level of skills such as secondary hematopoietic stem cell transplantation, haploidentical transplantation, cord blood transplantation, and cell separation transplantation addition to autologous hematopoietic stem cell transplantation, and sibling/non-related transplantation. Hematopoietic stem cell transplantation is the ultimate treatment method that gives recurrent/intractable hematologic malignancy patients hope of a complete cure. However, it is also a treatment technique with high risk, and so the infrastructure of an organically organized transplantation center and extensive experience of medical professionals are important. The Hematopoietic Stem Cell Transplantation Center at Seoul National University Cancer Hospital meets all the requirements.